Aldridge, Sarah J. http://orcid.org/0000-0002-5158-1242
Agrawal, Utkarsh
Murphy, Siobhán
Millington, Tristan
Akbari, Ashley http://orcid.org/0000-0003-0814-0801
Almaghrabi, Fatima
Anand, Sneha N.
Bedston, Stuart
Goudie, Rosalind
Griffiths, Rowena
Joy, Mark
Lowthian, Emily
de Lusignan, Simon http://orcid.org/0000-0002-8553-2641
Patterson, Lynsey
Robertson, Chris http://orcid.org/0000-0001-6848-5241
Rudan, Igor
Bradley, Declan T. http://orcid.org/0000-0003-1468-1823
Lyons, Ronan A. http://orcid.org/0000-0001-5225-000X
Sheikh, Aziz
Owen, Rhiannon K. http://orcid.org/0000-0001-5977-376X
Article History
Received: 24 May 2023
Accepted: 27 February 2024
First Online: 15 March 2024
Competing interests
: AS has served on a number of UK and Scottish government COVID-19 advisory bodies. CR has served on a number of UK and Scottish government COVID-19 advisory bodies—SPI-M, MHRA Covid Vaccines Benefit and Risk Group, Scottish Government Covid Advisory Group and Chief Nursing Officer Nosocomial Advisory Group. DTB has served on a number of UK and Northern Ireland government COVID-19 advisory bodies. All other authors report no competing interests. RAL was a member of the Welsh Government COVID-19 Technical Advisory Group. RKO is a member of the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee, member of the NICE Decision Support Unit (DSU), and associate member of the NICE Technical Support Unit (TSU). RKO has served as a paid consultant to the pharmaceutical industry, providing unrelated methodological advice generally. She reports teaching fees from the Association of British Pharmaceutical Industry (ABPI) and the University of Bristol. SdeL has received grants through his University for vaccine related research from AstraZeneca, GSK, Moderna, MSD, Sanofi and Seqirus. He has also been a member of advisory boards for AstraZeneca, GSK, Sanofi and Seqirus, with any funding paid to his University. The remaining authors have nothing to declare.